ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer Post author:admERY Post published:September 26, 2016 Post category:Newsroom ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer. You Might Also Like ERYTECH announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia July 4, 2013 ERYTECH announces data presentations at the American Society of Hematology 57th Annual Meeting November 5, 2015 ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update November 12, 2018
ERYTECH announces data presentations at the American Society of Hematology 57th Annual Meeting November 5, 2015